Drug profile · INN
sofpironium bromide
SOFDRA
sofpironium bromide (SOFDRA) is a muscarinic acetylcholine receptor inhibitor. Route of administration: topical. Current US regulatory status: approved.
Drug details — sofpironium bromide
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
sofpironium bromide (SOFDRA) is a muscarinic acetylcholine receptor inhibitor. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscarinic acetylcholine receptor inhibitor
Primary target: Muscarinic acetylcholine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is sofpironium bromide?
sofpironium bromide (SOFDRA) is a muscarinic acetylcholine receptor inhibitor. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for sofpironium bromide?
SOFDRA is a marketed brand name for sofpironium bromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sofpironium bromide?
sofpironium bromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.